**SUPPLEMENTARY DATA**

**Supplementary Table S1. Sex differences of patients who satisfied International Study Group for Behçet's Disease criteria**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| N=5565 |  | Men | Women | Comparison |
| N |  | 2138 | 3427 |  |
| Oral ulceration | YesNo UnclearPrevalence, % | 2138 (100.0)0 (0.0)0 (0.0)NA | 3427 (100.0)0 (0.0)0 (0.0)NA | NA |
| Skin lesions | YesNo Unclear Prevalence, % | 2029 (94.9)94 (4.4)15 (0.7)95.6 | 3270 (95.4)138 (4.0)19 (0.6)96.0 | OR 0.91 (0.70-1.19)P = 0.495 |
| Ocular lesions | YesNo Unclear Prevalence, % | 1145 (53.6)924 (43.2)69 (3.2)55.3 | 1054 (30.8)2242 (65.4)131 (3.8)32.0 | OR 2.64 (2.35-2.95)P < 0.001 |
| Genital ulceration | YesNo Unclear Prevalence, % | 1370 (64.1)699 (32.7)69 (3.2)66.2 | 2938 (85.7)431 (12.6)58 (1.7)87.2 | OR 0.29 (0.25-0.33)P < 0.001 |
| Positive pathergy test | YesNo Unclear Prevalence, % | 612 (28.6)736 (34.4)790 (37.0)45.4 | 880 (25.7)1350 (39.4)1197 (34.9)39.5 | OR 1.28 (1.11-1.46)P < 0.001 |
| Arthritis | YesNo Unclear Prevalence, % | 981 (45.9)1029 (48.1)128 (6.0)48.8 | 1877 (54.8)1410 (41.1)140 (4.1)57.1 | OR 0.72 (0.64-0.80)P < 0.001 |
| Gastrointestinal symptoms | YesNo Unclear Prevalence, % | 508 (23.8)1524 (71.3)106 (5.0)25.0 | 906 (26.4)2390 (69.7)131 (3.8)27.5 | OR 0.88 (0.78-0.998)P = 0.046 |
| Vascular lesions | YesNo Unclear Prevalence, % | 219 (10.2)1558 (72.9)361 (16.9)12.3 | 261 (7.6)2588 (75.5)578 (16.9)9.2 | OR 1.39 (1.15-1.69)P < 0.001 |
| Neurological manifestations | YesNo Unclear Prevalence, % | 401 (18.8)1633 (76.4)104 (4.9)19.7 | 767 (22.4)2540 (74.1)120 (3.5)23.2 | OR 0.81 (0.71-0.93)P < 0.001 |
| HLA-B51 positive | YesNo Unclear Prevalence, % | 515 (24.1)534 (25.0)1089 (50.9)49.1 | 604 (17.6)846 (24.7)1977 (57.7)41.7 | OR 1.35 (1.15-1.58)P < 0.001 |

All values listed as n (%) unless otherwise stated. Prevalence was judged from the Yes / (Yes + No) ignoring Unclear. Epididymitis was excluded from this table. OR: odds ratio evaluating females as reference; NA: Not applicable.

**Supplementary Table s2. Age differences of patients who satisfied International Study Group for Behçet's Disease criteria**

|  |  |  |  |
| --- | --- | --- | --- |
| N = 5565 | Manifestation (+) | Manifestation (-) |  |
|  | N | Median age (IQR) | N | Median age (IQR) | P |
| Skin lesions | 5299 | 38 (30-48) | 232 | 39.5 (30-52) | 0.446 |
| Ocular lesions | 2199 | 40 (32-51) | 3166 | 37 (29-47) | < 0.001 |
| Genital ulceration | 4308 | 38 (30-47) | 1130 | 40 (31.25-51) | < 0.001 |
| Positive pathergy test | 1492 | 38 (30-50) | 2086 | 37 (29-46) | 0.007 |
| Arthritis | 2858 | 39 (31-50) | 2439 | 37 (29-47) | < 0.001 |
| Epididymitis (men only) | 213 | 37 (30-46) | 1714 | 39 (31-51) | 0.076 |
| Gastrointestinal symptoms | 1414 | 39 (30-50) | 3914 | 38 (30-47) | 0.097 |
| Vascular lesions | 480 | 42 (33-55) | 4146 | 38 (30-47) | < 0.001 |
| Neurological manifestations | 1168 | 39 (31-49) | 4173 | 38 (30-48) | 0.098 |
| HLA-B51 positive | 1119 | 37 (29-48) | 1380 | 37 (29-45.25) | 0.513 |

Top row manifestation includes HLA-B51. Oral ulcer was removed from this table. P: Mann Whitney test.

**Supplementary Figure S1. Subgrouping by sex and age of patients who satisfied International Study Group for Behçet's Disease criteria**



A filled/open circle indicates estimated prevalence. An error bar indicates 95% confidence interval. Note that x axes were modified for each figure. M: male; F: female.